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Objective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) 
with emphasis on proton pump inhibitors (PPIs), particularly on delayed-release esomeprazole, 
and to identify properties and adverse effects of PPIs observed in the treatment of GERD in 
children and adolescents.
Sources: Electronic search of PubMed/Medline and Cochrane Collaboration databases, and of 
abstracts on DDW, NASPGHAN, and ESPGHAN. We focused on controlled and randomized 
studies published since 2000 and identified reviews that presented a consensual position, and 
directives published within the last 10 years.
Main results: PPIs are considered better antisecretory agents than H2-receptor antagonists. 
Although all PPIs are similar, they are not identical in their pharmacologic properties. For 
example, the acid-suppressive effect of esomeprazole, the S-isomer of omeprazole, persists for 
more than 16 hours after administration of the morning dose. Therefore, it can control acidity 
after night meals better than a single dose of omeprazole. Moreover, the onset of the suppressive 
effect of esomeprazole is faster. It achieves acid inhibition faster than other PPIs.
Conclusion: Currently, the mainstream treatment for GERD in children is a PPI. Although 
PPIs are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies 
with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion 
as omeprazole. It also seems that some pharmacologic properties of esomeprazole are actually 
better for the treatment of GERD.
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Introduction
The retrograde movement of gastric contents into the esophagus is a physiologic 
event called gastroesophageal reflux. Recently, evidence-based consensus has defined 
gastroesophageal reflux disease (GERD) in children. Consensus states that GERD in 
pediatric patients is present when the reflux of gastric contents is a cause of trouble-
some symptoms and/or complications.1,2 Symptoms of GERD vary with the age of 
the child. Heartburn and regurgitation are typical symptoms in adults and have high 
specificity for GERD.3 Many experts believe that these symptoms can be considered 
indicators of GERD in children older than eight years and in adolescents.4 However, 
in infants and preschool children, heartburn, regurgitation/vomiting, refusing   feeding, 
excessive crying, and abdominal pain are often associated with GERD, but these 
symptoms lack specificity.5
Regurgitation is present in 50% of normal infants and it alone does not indicate 
the presence of GERD. Irritability and frequent crying are often normal events and are Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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rarely related to GERD.6 Although the symptoms of GERD 
are less common than the symptoms of gastroesophageal 
reflux, the diagnosis of GERD is still prevalent. A prevalence 
study reported weekly heartburn sensation and acid regurgi-
tation in approximately 2% of children aged 3–9 years and 
in 5%–8% of children aged 10–17 years. Heartburn alone 
was identified in 17.8% of the children in the older age   
group.7
Erosive esophagitis is defined as the presence of 
endoscopically visible breaks in the esophageal mucosa 
at or immediately above the gastroesophageal junction. 
In adults, only 30% of patients with GERD have erosive 
disease.8 In children without an underlying disease, as well 
as in adults, erosive disease should correspond to a smaller 
proportion of cases within the general framework of the 
disease. However, in children with underlying conditions 
that favor the disease (ie, esophageal atresia, severe neu-
rologic disease, hiatal   hernia, chronic lung disease, first-
degree relatives with severe GERD), erosive esophagitis 
is more frequent. Chronic and severe reflux esophagitis in 
children may develop complications as occurs in adults. 
Esophageal stenosis should be suspected in patients with 
chronic complaints of progressive dysphagia. Barrett’s 
esophagus is very uncommon and it is mainly found when 
coexisting underlying conditions   predispose to a chronic   
disease.1
Research strategy
In 2006, we searched the PubMed/Medline and Cochrane 
Collaboration databases for the following keywords: gas-
troesophageal reflux and drug therapy, gastroesophageal 
reflux and omeprazole, lansoprazole, pantoprazole, ranitidine, 
cisapride, domperidone, metoclopramide, erythromycin; 
gastroesophageal reflux and esophagitis; gastroesophageal 
reflux and Barrett’s esophagus; gastroesophageal reflux 
and respiratory tract diseases, gastroesophageal reflux, and 
cough; gastroesophageal reflux and asthma.9 Subsequently, 
a search was run on the same databases and on abstracts 
of Digestive Disease week, North American Society for 
Pediatric Gastroenterology, Hepatology and Nutrition, and 
European Society for Paediatric Gastroenterology, Hepa-
tology and Nutrition, using the aforementioned words and 
esomeprazole. From these results, we selected controlled 
and randomized treatment studies, blind or otherwise, of 
children (,18 years of age), published from 2000 onwards, 
and reviews that presented consensual positions or directives, 
published in the last 10 years. Other articles judged to be 
of relevance, including uncontrolled treatment studies and 
citations found in the selected articles, were also consulted 
and included when appropriate. When pediatric literature 
was considered to be scarce or nonexistent, the literature on 
adults was also consulted. This review was limited to articles 
published in English.
Therapeutic management
The therapeutic management of GERD includes lifestyle 
changes, pharmacologic therapy, and surgery.
Lifestyle changes
Patients with GERD may take advantage of changes in 
lifestyle with or without drug treatment. A supine position 
without elevation, for example, has been recommended, 
whereas other positions seem to have significant risks or 
do not present any advantages.2,10,11–14 Thickened infant 
formula and the introduction of solid foods also reduce gas-
troesophageal reflux-related regurgitations. However, some 
studies have identified that the esophagus continues to be 
exposed to acid reflux. Furthermore, some infants may exhibit 
coughing or diarrhea as a consequence of thickened diets.10,15 
  Recommendations for older children and adolescents are 
based on those defined for adults. In terms of dietary restric-
tions, substances that cause an increased frequency of transi-
tory lower esophageal sphincter relaxation or that are able to 
exacerbate symptoms should be avoided, including, eg, caf-
feine, chocolate, spicy foods, and alcohol. In   addition, control 
of obesity, abstention from tobacco, and the   suspension of 
passive smoking are also recommended.16
Pharmacologic treatment
Principles of treatment
In the treatment of GERD, the usual aims are to relieve 
symptoms, improve the patient’s quality of life, heal mucosal 
lesions, and prevent recurrence and complications. The 
pharmacologic agents currently used for treating GERD 
in children are gastric acid buffering agents, prokinetics, 
and gastric antisecretory agents. Buffering agents are only 
used for the immediate relief of symptoms. Prokinetic 
agents were extensively used in the past because they 
increase the lower esophageal sphincter tonus. However, 
the pathophysiologic mechanism most strongly linked 
with GERD is increased frequency of transient relaxation 
of the lower esophageal sphincter. Because cisapride has 
been banned in most   countries, these agents have been 
less frequently used.   Currently, the major pharmacologic 
agents used for treating GERD are the gastric antisecretory   
agents.9Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Nonerosive esophagitis and suspected GeRD
Many clinical symptoms lead to the suspicion of GERD in 
infants and children. Although in certain circumstances it may 
not be the most likely diagnosis, in others, reflux esophagitis, 
particularly nonerosive esophagitis, is a   consistent cause 
of complaints. Finding irritable infants is a very common 
situation in clinical practice, and because diagnostic tests 
are limited to predict GERD in this setting,17,18 infants with 
persistent crying and irritability may be managed in one of 
three ways, ie, parents may be told that improvement will 
occur over time, additional investigation may be recom-
mended, and, finally, the use of drugs on a time-limited trial 
basis (two weeks) may be tried. However, empiric therapy 
has the potential risk of adverse effects, and clinical improve-
ment may be due to spontaneous symptom resolution or to 
a placebo effect.2
Complaints of recurrent vomiting, abdominal pain, and 
dysphagia require corroborative diagnostic tests, usually 
upper endoscopy with biopsy (for differential diagnosis) or 
24-hour esophageal pH monitoring.
Asthma is also a high prevalence disease and, within 
these patients, abnormal 24-hour pH manometry is usual. 
Furthermore, asthma and GERD may coexist without a 
causal relationship. GERD with esophageal symptoms should 
always be treated in patients with or without asthma,9,19–21 
and GERD should be considered a causal factor (precipitat-
ing or aggravating) of asthma only in difficult-to-treat cases 
(especially in patients with nocturnal symptoms of asthma 
and esophageal complaints).2 In these settings, the presence 
of clinical symptoms and tests confirming the pathologic 
presence of acid or nonacid contents in the esophagus, even 
without endoscopic changes, lead to the pharmacologic 
  treatment of nonerosive esophagitis.
In contrast, children older than eight years of age and 
adolescents complaining of heartburn should be initially 
approached as having GERD, and pharmacologic treatment 
should be instituted without the need of further diagnostic 
tests. If regurgitation is also present, the specificity for GERD 
becomes even higher.1,3 Endoscopy should be performed 
only if the symptoms do not improve after 2–4 weeks of 
treatment, if there is resistance to drug withdrawal, or if the 
symptoms recur after discontinuation of medication.2 In all of 
these settings, treatment should be aimed at the suppression 
of gastric acidity, and in this case, proton pump inhibitor 
(PPIs) are the most recommended drugs.
GERD may or may not have a chronic course.22 Patients 
who have underlying diseases (ie, hiatal hernia, repaired 
esophageal atresia, central nervous system impairment, 
chronic lung disease) or who have first-degree relatives with 
severe and chronic illnesses are more likely to present this 
kind of evolution.23 In infants with GERD, one should wait 
for the acquisition of developmental marks associated with 
maturation of the antireflux barrier before discontinuing 
pharmacologic therapy. In other cases, GERD should be 
initially approached as a disease that can be treated with a 
3–6-month course of pharmacologic treatment. Resistance 
to drug withdrawal and recurrence of symptoms points to a 
chronic course.
erosive esophagitis
Gastric antisecretory agents are usually successful in treating 
GERD. It is possible that inadequate or delayed treatment 
of erosive esophagitis increases the risk of manifestation 
of other diseases, such as esophageal stricture.9 The main 
antisecretory agents currently used in children are PPIs and 
H2-receptor antagonists.
PPIs are considered better antisecretory agents than 
H2-receptor antagonists. A meta-analysis of studies in adults 
has shown that 77% of patients became symptom-free at 
eight weeks, compared with 48% of those taking H2-receptor 
antagonists.24 Moreover, other studies with adults have con-
firmed the superiority of PPIs over H2-receptor antagonists 
for healing severe esophagitis. However, for many years, only 
H2-receptor antagonists (especially ranitidine) were used in 
children, and until today there are few studies comparing the 
use of PPIs with H2-receptor antagonists in this age group.
In a randomized study, Cucchiara et al compared raniti-
dine with omeprazole.25 No significant difference in healing 
rates were observed between these groups. However, in their 
study, the dose of omeprazole was low (40 mg/1.73 m2) and 
the dose of ranitidine was very high (20 mg/kg/day). Other 
studies have shown that a significant number of patients with 
esophagitis did not heal with such a low dose of omeprazole.26 
Omeprazole at doses starting at 0.7 mg/kg/day are already 
effective in healing esophageal erosion.
Hassal et al achieved healing of erosion with   omeprazole 
doses ranging from 0.7 to 3.5 mg/kg/day. A 0.7 mg/kg/day dose 
cured esophagitis in 44% of patients and a 1.4 mg/kg/day dose 
healed it in 28% of patients. Cure occurred after 90 ± 30 days 
of reaching the healing dose. Symptoms improved within the 
first two weeks of treatment.26
Despite the need of further randomized and controlled 
trials in the use of PPIs, clinical experience with omeprazole 
keeps on growing. Lansoprazole was the second PPI to be 
cleared for pediatric use by the Food and Drug Administra-
tion (FDA), and it has been effective in healing esophageal Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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erosion in children27 and adolescents.2 Thus, omeprazole is 
recommended at a dosage of 0.7–3.5 mg/kg/day, for an aver-
age period of three months. Lansoprazole, starting at a dosage 
of 15 mg/day, partially improves symptoms of nonerosive 
esophagitis, and a dosage of 1.5 mg/kg/day or 30 mg/day 
seems to be effective in healing esophageal erosion.27,28
In adults, besides omeprazole, other drugs such as lanso-
prazole, pantoprazole, rabeprazole, and esomeprazole have 
been used to treat GERD.8 Recently, studies with children 
using pantoprazole,29 rabeprazole,30 and esomeprazole31 have 
also been published.32 PPIs currently approved for use in 
children in North America are omeprazole, lansoprazole, and 
esomeprazole. At the moment, only omeprazole and esome-
prazole have been approved in Europe. No PPI has been 
approved for use in infants younger than one year of age.
In adults with erosive esophagitis, esomeprazole 40 mg 
can offer higher healing rates when compared with those 
achieved by the standard doses of omeprazole 20 mg, lanso-
prazole 30 mg, and pantoprazole 40 mg.33–36
Recently, improvement of symptoms in adolescents 
clinically diagnosed with GERD was evaluated using 20 mg 
and 40 mg of esomeprazole. Symptom scores decreased 
significantly in both groups by the final week of treatment. 
At baseline, 63.1% of patients had moderate to severe 
symptoms, while at the final visit, this number decreased 
to 9.3% (P , 0.0001).37 Similarly, improvement of symp-
toms were tested in children with endoscopically proven 
GERD using esomeprazole. Patients aged 1–11 years 
received 5 mg or 10 mg of esomeprazole if they weighed 
less than 20 kg, and 10 mg or 20 mg if they weighed more 
than 20 kg. Of the 58 patients with moderate to severe 
symptoms, 91.4% had improved by the final week of   
treatment.31
It is usual for GERD to relapse when treatment is with-
drawn. Approximately 80% of adult patients relapse after 
six to 12 months, requiring the long-term use of gastric acid 
suppressants.38
It is important to point out that the most common errors 
when prescribing PPIs are subtherapeutic dosages, and failure 
to follow the recommendations about administration. PPIs 
must be taken once a day before breakfast. Administration to 
young children requires opening the enteric-coated capsules, 
and the contents must be diluted in acid beverages, according 
to some authors.39
In case of limited response to treatment, one should 
review the prescribed dosage, verify if there has been compli-
ance with treatment, and check the diagnosis. Eosinophilic 
esophagitis should always be kept in mind in such cases.
Maintenance therapy is still under discussion. After the 
healing of erosive esophagitis, adults with mild symptoms 
can be managed with on-demand therapy. Boccia et al studied 
children with erosive esophagitis and found no difference 
in recurrence of esophagitis and symptoms in children on 
maintenance therapy with omeprazole (half of the dose used 
during the healing phase of the injury), in those on mainte-
nance therapy with ranitidine, and in those not using any 
drugs. The presence of an underlying condition that might 
be triggering the development of a chronic disease should be 
considered when prescribing maintenance therapy.40
Evaluation of cost-effectiveness is also a relevant aspect 
and should be considered in the choice of starting and main-
taining treatment schemes. The estimated annual cost of PPI 
use is several billion dollars.41 In adults, on-demand strategies 
present the best cost-effectiveness relation for maintenance 
treatment of GERD, especially for those adults with mild 
symptoms.41,42 Studies, in children, evaluating success 
rate, cost-effectiveness, and risks of the different treatment 
schemes are scarce. Hopefully, in the near future, such studies 
will be able to guide GERD treatment in pediatrics.
PPIs and H2-receptor antagonists
The postprandial acid inhibition produced by H2-receptor 
antagonists is only partial. In contrast, PPIs are able to 
inhibit meal-induced acid secretion. Gastric pH begins to 
increase within 30 minutes of administration of H2-receptor 
antagonists, and acid suppression lasts 4–8 hours.8 Most 
available PPIs are therefore regarded as “delayed-release” 
preparations, and maximal acid suppressant effect can take 
up to four days to be reached. However, PPIs maintain 
intragastric pH $ 4 for longer periods of time. Reduction 
of acid secretion caused by H2-receptor antagonists is less 
pronounced and lasts less time than that caused by PPIs, but 
H2-receptor antagonists are better for the immediate relief 
of symptoms.2,8
The powerful action of PPIs, in addition to elevating gas-
tric pH, also leads to reducing 24-hour intragastric volume, 
facilitating gastric emptying, and reducing refluxate volume. 
The only PPIs used in children are enteric-coated capsules 
and the multiple-unit pellet system. The capsules contain 
delayed-release granules, which should not be chewed or 
ground up because they are acid-labile. There is no liquid 
preparation. The ideal regime for a PPI is one dose a day, 
before the first meal, because that is when proton pumps are 
generated and can be most effectively blocked. A second dose 
may be recommended with the evening meal in the presence 
of severe esophagitis, peptic stricture, esophageal motility Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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disorders, persistent nocturnal reflux, and extraesophageal 
GERD. However, data on extraesophageal GERD are incon-
clusive and more studies are needed to assess   treatment 
regimens.43
Tolerance has been observed with H2-receptor antago-
nists, but not with PPIs. Ranitidine can induce tolerance 
within five days of use.44 Tolerance is probably due to increase 
of gastrin. PPIs act at the final site of acid production, so 
these drugs block the effect of any compensatory mechanisms 
promoting acid secretion.45
PPIs are similar drugs but not identical in their phar-
macologic properties. Esomeprazole is the S-isomer of 
omeprazole. It inhibits acid production faster than other 
PPIs46 and, as a result, there is faster symptom relief. 
  Clinically relevant benchmark effects on acid secretion 
include the magnitude of this effect, the consistency of this 
effect amongst individuals, and the duration over which the 
desired effect is maintained. Compared with omeprazole 
20 mg, esomeprazole 20 mg and 40 mg have been shown 
to produce superior outcomes on these three key measures 
of antisecretory effect.47 However, the clinical relevance 
of these effects, particularly for patients with nonerosive 
esophagitis, is not yet clear. The pharmacokinetic proper-
ties of esomeprazole have been evaluated in adolescents, 
children, infants, preterm infants, and term neonates 
with GERD.31,37,47–49 Despite the small number of patients 
involved in these studies, the pharmacokinetic parameters of 
esomeprazole proved to be dose- and time-dependent, and 
this might be due to the fact that young children have a faster 
metabolism of esomeprazole per kilogram of body weight 
than older children. In preterm infants and term neonates, 
esomeprazole produces no changes in the characteristics 
of the bolus reflux despite its significant acid suppression 
effects.49 It can be concluded that esomeprazole, in children, 
can have the same advantages of GERD treatment observed 
in adults. The magnitude of this acid-suppressive effect 
persists for more than 16 hours after the morning dose, 
allowing control of esophageal acidity after night meals.47 
Moreover, the onset of the suppressive effect is faster with 
esomeprazole. In adults, responses vary much less among 
individuals than with omeprazole. This effect cannot be 
observed in young infants up to 12 months of age.49 Whilst 
having similar structures, PPIs differ in their metabolism. 
PPIs, mainly omeprazole, are metabolized to different 
degrees by the P450 hepatic enzyme system, specifically by 
the CYP2C19 and CYP3A4 enzymes. Significant features 
of the pharmacokinetics and pharmacodynamics of PPIs 
are related to the genetic polymorphism of these enzymes, 
which affects the biotransformation and plasma elimination 
of PPIs. Genetic polymorphism can lead to major differ-
ences in the kinetics of PPIs. Individuals who metabolize 
these drugs poorly may experience greater effects of 
the dose used. Thus, a proportion of the great variation 
observed in PPI trials in children could be explained by 
these findings.50,51
Adverse effects related to PPIs in children include 
headaches, diarrhea, abdominal pain, nausea, skin rash, 
constipation, elevated transaminase levels, and proteinuria.51 
Recently, the safety of esomeprazole 20 mg and 40 mg were 
evaluated in 148 adolescents with GERD. Adverse events 
were reported by 75% and 78% of the patients, respectively. 
However, only 14.9% of the adverse effects were considered 
related to the treatment.37 In children aged 1–11 years with 
GERD and treated with esomeprazole, none of the adverse 
effects that occurred were considered related to treatment.31 
Acid suppression due to the use of H2-receptor antagonists 
and PPIs may be associated with community-acquired 
pneumonia and gastroenteritis in children.52 In adults, PPIs 
have been shown to alter the gastric and intestinal micro-
biota53 and to cause acute interstitial nephritis.54 In children, 
this effect has not been reported. Hypergastrinemia and 
parietal cell hyperplasia have been observed with PPIs. 
However, these findings do not have any clinically relevant 
implications.51
Because PPIs are sometimes administered simultaneously 
with many drugs, it is important to consider their interactions 
with other drugs. As a result of the intense reduction in gas-
tric acidity, PPIs can reduce the bioavailability of drugs that 
require lower pH values to be absorbed, such as ampicillin, 
cyanocobalamin, iron, digoxin, and ketoconazole.
Conclusion
Current treatment of GERD is based on the use of gastric 
antisecretory drugs, mainly PPIs. Delayed-release esome-
prazole retains the powerful gastric inhibitory action of 
omeprazole, but has longer lasting effects and is faster in 
the onset of its effects. In a single-administration scheme, 
esomeprazole may have advantages over other PPIs. 
No adverse effects, different from the already known 
effects of PPIs, have been observed, so far, in studies with 
children and adolescents. However, the number of random-
ized controlled therapeutic trials in   children is still small. 
Future studies should take down the current statements for 
the disease so that the outcome variables can be compared. 
Surgery may be recommended in very specific cases as an 
adjuvant treatment with PPIs.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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